Inflammation and dopaminergic neuronal loss in Parkinson's disease: A complex matter

Experimental Neurology

Volumn 184, Issue 2, 2003, Pages 561-564

  Hartmann, Andreas ^a   Hunot, Stéphane ^a   Hirsch, Etienne C ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DEXAMETHASONE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDOPAMINE; PIOGLITAZONE;

BRAIN REGION; CELL ACTIVATION; CELL ACTIVITY; CELL LOSS; CLINICAL TRIAL; DOPAMINERGIC NERVE CELL; DRUG RESEARCH; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; GLIA CELL; HUMAN; INFLAMMATION; MACROPHAGE; MICROGLIA; MOLECULAR DYNAMICS; NERVE CELL NECROSIS; NONHUMAN; NOTE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA;

EID: 0842277733     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2003.08.004     Document Type: Note

References (32)

1. Anglade P., Vyas S., Javoy-Agid F., Herrero M.T., Michel P.P., Marquez J., Mouatt-Prigent A., Ruberg M., Hirsch E.C., Agid Y. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 12:1997;25-31.
2. Boka G., Anglade P., Wallach D., Javoy-Agid F., Agid Y., Hirsch E.C. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci. Lett. 172:1994;151-154.
3. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., Hirsch E.C. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 82:2002;615-624.
4. Bronstein D.M., Perez-Otano I., Sun V., Mullis Sawin S.B., Chan J., Wu G.C., Hudson P.M., Kong L.Y., Hong J.S., McMillian M.K. Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures. Brain Res. 704:1995;112-116.
5. Castano A., Herrera A.J., Cano J., Machado A. The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. J. Neurochem. 81:2002;150-157.
6. Du Y., Ma Z., Lin S., Dodel R.C., Gao F., Bales K.R., Triarhou L.C., Chernet E., Perry K.W., Nelson D.L., Luecke S., Phebus L.A., Bymaster F.P., Paul S.M. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98:2001;14669-14674.
7. Hartmann A., Hirsch E.C. Parkinson's disease. The apoptosis hypothesis revisited. Adv. Neurol. 86:2001;143-153.
8. He Y., Appel S., Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res. 909:2001;187-193.
9. Herrera A.J., Castano A., Venero J.L., Cano J., Machado A. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol. Dis. 7:2000;429-447.
10. Hirsch E.C., Faucheux B., Damier P., Mouatt-Prigent A., Agid Y. Neuronal vulnerability in Parkinson's disease. J. Neural Transm., Suppl. 50:1997;79-88.
11. Hirsch E.C., Breidert T., Rousselet E., Hunot S., Hartmann A., Michel P.P. The role of glial reaction and inflammation in Parkinson's disease. Ann. N.Y. Acad. Sci. 991:2003;214-228.
12. Hunot S., Dugas N., Faucheux B., Hartmann A., Tardieu M., Debre P., Agid Y., Dugas B., Hirsch E.C. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J. Neurosci. 19:1999;3440-3447.
13. Hunot S., Hartmann A., Hirsch E.C. The inflammatory response in the Parkinson brain. Clin. Neurosci. Res. 1:2001;434-443.
14. Hurley S.D., O'Banion M.K., Song D.D., Arana F.S., Olschowka J.A., Haber S.N. Microglial response is poorly correlated with neurodegeneration following chronic, low-dose MPTP-administration in monkeys. Exp. Neurol. 184:2003;659-668.
15. Jenner P., Olanow C.W. Understanding cell death in Parkinson's disease. Ann. Neurol. 44(3 Suppl. 1):1998;S72-S84.
16. Kim W.G., Mohney R.P., Wilson B., Jeohn G.H., Liu B., Hong J.S. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J. Neurosci. 20:2000;6309-6316.
17. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
18. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46:1999;598-605.
19. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., Dawson V.L., Dawson T.M., Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5:1999;1403-1409.
20. McGeer P.L., McGeer E.G. Mechanisms of cell death in Alzheimer disease-immunopathology. J. Neural Transm., Suppl. 54:1998;159-166.
21. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 38:1988;1285-1291.
22. McNaught K.S., Jenner P. Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures. J. Neurochem. 73:1999;2469-2476.
23. Mochizuki H., Goto K., Mori H., Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J. Neurol. Sci. 137:1996;120-123.
24. Nagatsu T., Mogi M., Ichinose H., Togari A. Cytokines in Parkinson's disease. J. Neural Transm., Suppl. 58:2000;143-151.
25. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22:1999;123-144.
26. Ravina B.M., Fagan S.C., Hart R.G., Hovinga C.A., Murphy D.D., Dawson T.M., Marler J.R. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology. 60:2003;1234-1240.
27. Schapira A.H., Gu M., Taanman J.W., Tabrizi S.J., Seaton T., Cleeter M., Cooper J.M. Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann. Neurol. 44(3 Suppl. 1):1998;S89-S98.
28. Stoll G., Jander S., Schroeter M. Detrimental and beneficial effects of injury-induced inflammation and cytokine expression in the nervous system. Adv. Exp. Med. Biol. 513:2002;87-113.
29. Tatton N.A., Maclean-Fraser A., Tatton W.G., Perl D.P., Olanow C.W. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann. Neurol. 44(3 Suppl. 1):1998;S142-S148.
30. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., Vila M., Jackson-Lewis V., Przedborski S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 100:2003;5473-5478.
31. Vila M., Wu D.C., Przedborski S. Engineered modeling and the secrets of Parkinson's disease. Trends Neurosci. 24(11 Suppl.):2001;S49-S55.
32. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22:2002;1763-1771.